SMO and skin basal cell carcinoma: This is reflected by the approval of the first SMO inhibitor vismodegib (GDC-0449, ERIVEDGETM) in 2012 for the treatment of locally advanced and metastatic BCC [23–27], followed by the approval of sonidegib (LDE225, ODOMZOTM) after having shown therapeutic efficacy in BCC patients [28–31].